🏛️ Verified NIH Record • Updated 2026-08-04

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer (NCT01081951)

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (3 items) and avoid the listed exclusions (3 items).

Location: Research Site — Stanford, California

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Patients receiving any systemic anticancer chemotherapy, radiotherapy (except palliative) within two weeks from the last dose prior to study treatment
  • Hypersensitivity to pre medications required for treatment with paclitaxel/carboplatin

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (53 Sites)

  • Research Site — Stanford, California
  • Research Site — West Hollywood, California
  • Research Site — Orlando, Florida
  • Research Site — Indianapolis, Indiana
  • Research Site — Boston, Massachusetts
  • Research Site — Boston, Massachusetts
  • Research Site — New York, New York
  • Research Site — Portland, Oregon
  • Research Site — Parkville,
  • Research Site — Randwick,
  • Research Site — Brussels,
  • Research Site — Leuven,
  • Research Site — Namur,
  • Research Site — Wilrijk,
  • Research Site — Vancouver, British Columbia
  • Research Site — Hamilton, Ontario
  • Research Site — Toronto, Ontario
  • Research Site — Toronto, Ontario
  • Research Site — Québec, Quebec
  • Research Site — Sherbrooke, Quebec
  • Research Site — Brno,
  • Research Site — Brno,
  • Research Site — Hradec Králové,
  • Research Site — Olomouc,
  • Research Site — Prague,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗